SPECTRUM PHARMACEUTICALS, INC.

(SPPI)
  Report
Delayed Nasdaq  -  05/27 04:00:00 pm EDT
0.7375 USD   +4.57%
05/26Spectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predictive Capabilities of ctDNA as a Biomarker for Poziotinib Treatment Response
BU
05/25SPECTRUM PHARMACEUTICALS : Current Corporate Presentation
PU
05/17SPECTRUM PHARMACEUTICALS INC Change in Directors or Principal Officers (form 8-K/A)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Spectrum Pharmaceuticals : Current Corporate Presentation

09/09/2021 | 01:12pm EDT

Spectrum Pharmaceuticals

A Biopharmaceutical Company Developing Targeted and Novel Therapies in Oncology

Joe Turgeon | CEO

September 2021 | Investor Presentation

Safe Harbor Statement

This presentation contains forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include but are not limited to statements that relate to our business and its future, our strategy, the success of our drug candidates, the safety and efficacy of our drug products, product approvals, market potential, product sales, revenue, development, regulatory and approval timelines, product launches, product acquisitions, capital resources and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact.

Risks that could cause actual results to differ include the possibility that our existing and new drug candidates may not prove safe or effective, the possibility that our existing and new drug candidates may not receive approval from the FDA and other regulatory agencies in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that price and other competitive pressures may make the marketing and sale of our drugs not commercially feasible, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of sustained revenue history, our limited experience in establishing strategic alliances, our limited marketing experience, our customer concentration, the possibility for fluctuations in customer orders, evolving market dynamics, our dependence on third parties for clinical trials, manufacturing, distribution, information and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this presentation except as required by law.

2

Spectrum's Pipeline & Key Milestones

Targeted & Novel Medicines

ROLONTIS®

POZIOTINIB

Focused Interferon

(eflapegrastim)

Therapeutics (FIT)

Remediation of CRL

NDA Filing in 2021

Phase 1 Dose

Underway

Escalation Study

3

ROLONTIS is a Novel Product with a Unique Molecular Structure

4

ROLONTIS Demonstrated an Effect on Incidence and Duration of Severe Neutropenia

Two Phase 3 Fixed Dose Non-inferiority Studies with Eflapegrastim and Pegfilgrastim: ADVANCE-301 (N=406) & RECOVER-302 (N=237)

Primary Endpoint: Duration of Severe Neutropenia

PATIENTS

30

25

Incidence of SN in Cycle 1

242424

20

0.5

0.4

Duration of SN in Cycle 1

0.39

0.35

PERCENT OF

20

15

10

5

0

16

18

Mean Days

0.3

0.2

0.1

0

0.31

0.2

SPI-GCF-301SPI-GCF-302 Integrated

Eflapegrastim

Pegfilgrastim

SPI-GCF-301SPI-GCF-302

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Spectrum Pharmaceuticals Inc. published this content on 09 September 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 September 2021 17:11:05 UTC.


© Publicnow 2021
All news about SPECTRUM PHARMACEUTICALS, INC.
05/26Spectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predic..
BU
05/25SPECTRUM PHARMACEUTICALS : Current Corporate Presentation
PU
05/17SPECTRUM PHARMACEUTICALS INC Change in Directors or Principal Officers (form 8-K/A)
AQ
05/17SPECTRUM PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financial Statem..
AQ
05/17Spectrum Pharmaceuticals to Participate in H.C. Wainwright Global Investment Conference
BU
05/12TRANSCRIPT : Spectrum Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 12, 2022
CI
05/12SPECTRUM PHARMA : Q1 Earnings Snapshot
AQ
05/12Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corp..
BU
05/12Spectrum Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended Mar..
CI
05/11Spectrum Pharmaceuticals Names Nora Brennan CFO
MT
More news
Analyst Recommendations on SPECTRUM PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 7,29 M - -
Net income 2022 -90,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,46x
Yield 2022 -
Capitalization 130 M 130 M -
Capi. / Sales 2022 17,8x
Capi. / Sales 2023 1,16x
Nbr of Employees 164
Free-Float 89,8%
Chart SPECTRUM PHARMACEUTICALS, INC.
Duration : Period :
Spectrum Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SPECTRUM PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 0,74 $
Average target price 5,60 $
Spread / Average Target 659%
EPS Revisions
Managers and Directors
Thomas J. Riga President, CEO, CFO & Director
William L. Ashton Chairman
Francois Lebel Chief Medical Officer & Executive Vice President
Lyndah K. Dreiling Senior Vice President-Clinical Development
Dolatrai M. Vyas Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
SPECTRUM PHARMACEUTICALS, INC.-41.93%124
MODERNA, INC.-41.86%54 016
LONZA GROUP AG-28.07%42 292
IQVIA HOLDINGS INC.-21.85%39 319
SEAGEN INC.-8.54%25 487
ICON PUBLIC LIMITED COMPANY-26.61%17 693